{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:45:49Z","timestamp":1793090749594,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the prevalence of active tuberculosis (TB) infection in Moroccan patients with rheumatic diseases under biologic therapy, and to describe the demographic characteristics of these patients as well as to explore potential risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This 14-year nationally representative multicenter study enrolled Moroccan patients with rheumatic diseases who had been treated with biologic therapy. Patient medical records were reviewed retrospectively for demographic characteristics, underlying rheumatic diseases, associated comorbidities, and TB-related data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 1407 eligible patients were studied, detailed records were obtained for only 130 patients; 33 cases with active TB were identified at an estimated prevalence rate of 2.3%. The mean age was 42.9 \u00b1 12 years and 75.8% were males. Ankylosing spondylitis accounted for 84.8% of active TB cases, and the majority of the cases (31\/33) occurred among antitumor necrosis factor-alpha (TNF-\u03b1) users. A total of 8 out of 33 patients were positive at initial latent TB infection (LTBI) screening by tuberculin skin test and\/or interferon-gamma release assay. Consumption of unpasteurized dairy products (odds ratio [OR], 34.841; 95% confidence interval [CI], 3.1\u2013389.7;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.04), diabetes (OR, 38.468; 95% CI, 1.6\u2013878.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0,022), smoking (OR, 3.941; 95% CI, 1\u2013159.9;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.047), and long biologic therapy duration (OR, 1.991; 95% CI, 1.4\u201316.3;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) were identified as risk factors for developing active TB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Moroccan patients with rheumatic diseases under anti-TNF-\u03b1 agents are at an increased TB risk, especially when risk factors are present. Strict initial screening and regular monitoring of LTBI is recommended for patients living in high TB prevalence areas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_153_20","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T06:10:54Z","timestamp":1655187054000},"page":"175-182","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Active Tuberculosis Infection in Moroccan Patients with Rheumatic Diseases under Biologic Therapy"],"prefix":"10.4103","volume":"11","author":[{"given":"Ilham","family":"Aachari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifa","family":"Tahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gehan","family":"Elolemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Z.","family":"Taik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloua","family":"Afilal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Fellous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihad M.","family":"Berkchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Rkain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Bahiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahim","family":"Majjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lahsen","family":"Achemlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumaya","family":"Ousehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawtar","family":"Nassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouafa","family":"Mkinsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Z.","family":"Mahha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmae","family":"El Aissaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Chaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Harzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Youssoufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasna","family":"Hassikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anass","family":"Kherrab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radouane","family":"Niamane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalila","family":"Eddarami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ichchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Ghozlani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"El Bouchti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Z.","family":"Abourazzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Razine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadoua","family":"Allali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-7-20240902","doi-asserted-by":"crossref","first-page":"S629","DOI":"10.1093\/infdis\/jix362","article-title":"what we know about tuberculosis transmission: An overview","volume":"216","author":"Churchyard","year":"2017","journal-title":"J Infect Dis"},{"key":"R4-7-20240902","first-page":"889","article-title":"Update on latent tuberculosis infection","volume":"89","author":"Hartman-Adams","year":"2014","journal-title":"Am Fam Physician"},{"key":"R5-7-20240902","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R6-7-20240902","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2013-204960","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","volume":"74","author":"Arkema","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R7-7-20240902","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1093\/rheumatology\/keu172","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: A systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford"},{"key":"R8-7-20240902","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1146\/annurev-immunol-093019-010426","article-title":"The Innate Immune Response to Mycobacterium tuberculosis Infection","volume":"39","author":"Ravesloot-Ch\u00e1vez","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"R9-7-20240902","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R10-7-20240902","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R11-7-20240902","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jbspin.2005.10.004","article-title":"The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFalpha therapy","volume":"72","author":"Tubach","year":"2005","journal-title":"Joint Bone Spine"},{"key":"R12-7-20240902","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.autrev.2008.07.011","article-title":"Screening for tuberculosis infection prior to initiation of anti-TNF therapy","volume":"8","author":"Lalvani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"R13-7-20240902","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/ard.62.8.791","article-title":"French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R16-7-20240902","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.5588\/ijtld.15.0087","article-title":"Increased risk of pulmonary and extra-pulmonary tuberculosis in patients with rheumatic diseases","volume":"19","author":"Lu","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"R17-7-20240902","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.3899\/jrheum.110373","article-title":"Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers","volume":"38","author":"Kim","year":"2011","journal-title":"J Rheumatol"},{"key":"R18-7-20240902","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1136\/annrheumdis-2011-200489","article-title":"Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF\u03b1 inhibitors: The utility of IFN\u03b3 assay","volume":"71","author":"Chen","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R19-7-20240902","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/s10165-004-0281-x","article-title":"Clinical characteristics of Mycobacterium tuberculosis infection among rheumatoid arthritis patients","volume":"14","author":"Yoshinaga","year":"2004","journal-title":"Mod Rheumatol"},{"key":"R20-7-20240902","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/0885066620917588","article-title":"Mortality of Sepsis in Patients With Rheumatoid Arthritis: A Single-Center Retrospective Analysis and Comparison With a Control Group","volume":"36","author":"Krasselt","year":"2021","journal-title":"J Intensive Care Med"},{"key":"R21-7-20240902","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/030097402760375205","article-title":"Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong","volume":"31","author":"Tam","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"R22-7-20240902","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/acr.23487","article-title":"Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis, and psoriatic arthritis in Sweden: A population-based cohort study","volume":"70","author":"de Vries","year":"2018","journal-title":"Arthritis Care Res (Hoboken"},{"key":"R23-7-20240902","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10067-006-0286-2","article-title":"Pulmonary involvement in ankylosing spondylitis","volume":"26","author":"Sampaio-Barros","year":"2007","journal-title":"Clin Rheumatol"},{"key":"R24-7-20240902","doi-asserted-by":"crossref","first-page":"8909834","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"2017","author":"Cantini","year":"2017","journal-title":"Mediators Inflamm"},{"key":"R25-7-20240902","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1128\/CVI.00132-07","article-title":"Discrepancy between Mycobacterium tuberculosis-specific gamma interferon release assays using short and prolonged in vitro incubation","volume":"14","author":"Leyten","year":"2007","journal-title":"Clin Vaccine Immunol"},{"key":"R26-7-20240902","first-page":"662","article-title":"Discordant tuberculin skin and interferon-gamma tests during contact investigations: A dilemma for tuberculosis controllers","volume":"13","author":"O'Neal","year":"2009","journal-title":"Int J Tuberc Lung Dis"},{"key":"R27-7-20240902","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3899\/jrheum.140101","article-title":"Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations","volume":"91","author":"Iannone","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"R28-7-20240902","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.crohns.2012.05.012","article-title":"Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening","volume":"7","author":"Jauregui-Amezaga","year":"2013","journal-title":"J Crohns Colitis"},{"key":"R29-7-20240902","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/ibd.21605","article-title":"Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection","volume":"17","author":"B\u00e9lard","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"R30-7-20240902","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R31-7-20240902","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R32-7-20240902","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): Effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J Rheumatol"},{"key":"R33-7-20240902","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R34-7-20240902","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3899\/jrheum.081041","article-title":"Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections","volume":"36","author":"Aggarwal","year":"2009","journal-title":"J Rheumatol"},{"key":"R35-7-20240902","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: Structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R36-7-20240902","first-page":"40","article-title":"Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment","volume":"74","author":"Dinarello","year":"2005","journal-title":"J Rheumatol Suppl"},{"key":"R37-7-20240902","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.3899\/jrheum.090150","article-title":"Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial","volume":"36","author":"Park","year":"2009","journal-title":"J Rheumatol"},{"key":"R38-7-20240902","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S2213-2600(17)30060-7","article-title":"Serial QuantiFERON testing and tuberculosis disease risk among young children: An observational cohort study","volume":"5","author":"Andrews","year":"2017","journal-title":"Lancet Respir Med"},{"key":"R39-7-20240902","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.rbr.2017.05.003","article-title":"Incidence of tuberculosis among patients with rheumatoid arthritis using TNF blockers in Brazil: Data from the Brazilian Registry of Biological Therapies in Rheumatic Diseases (Registro Brasileiro de Monitora\u00e7\u00e3o de Terapias Biol\u00f3gicas-BIOBADABRASIL)","volume":"57","author":"Yonekura","year":"2017","journal-title":"Rev Bras Reumatol (English Edition"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_153_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:00:29Z","timestamp":1787756429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_153_20"}},"subtitle":["a Multicenter National Study"],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_153_20","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}